LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Home・Akciju saraksts・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Slēgts

SektorsVeselības aprūpe

186.03 -0.63

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

184.62

Max

190.84

Galvenie mērījumi
By Trading Economics
Ienākumi	2.9M 56M
Pārdošana	-27M 1B
P/E Sektora vidējais	592.3 77.671
EPS	2.43
Peļņas marža	5.529
Darbinieki	18,700
EBITDA	-23M 198M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+3.5% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	407M 9.2B
Iepriekšējā atvēršanas cena	186.66
Iepriekšējā slēgšanas cena	186.03

Ziņu noskaņojums

By Acuity

50%

182 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

117.16 / 144.77 Atbalsts un pretestība

Charles River Laboratories International Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 9. dec. 22:13 UTC

Peļņas

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

2025. g. 9. dec. 21:40 UTC

Peļņas

GameStop Sales Fall as Collectibles Remain Only Bright Spot

2025. g. 9. dec. 18:51 UTC

Iegādes, apvienošanās, pārņemšana

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

2025. g. 9. dec. 16:57 UTC

Galvenie tirgus virzītāji

Clear Secure Rises on Medicare Identity Verification Contract

2025. g. 9. dec. 23:46 UTC

Tirgus saruna

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

2025. g. 9. dec. 23:46 UTC

Iegādes, apvienošanās, pārņemšana

Legend Holdings Stake in Lenovo Now at 32.34%

2025. g. 9. dec. 23:45 UTC

Iegādes, apvienošanās, pārņemšana

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

2025. g. 9. dec. 23:44 UTC

Iegādes, apvienošanās, pārņemšana

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

2025. g. 9. dec. 23:43 UTC

Iegādes, apvienošanās, pārņemšana

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

2025. g. 9. dec. 23:43 UTC

Iegādes, apvienošanās, pārņemšana

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

2025. g. 9. dec. 23:35 UTC

Tirgus saruna

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

2025. g. 9. dec. 22:42 UTC

Peļņas

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

2025. g. 9. dec. 21:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 9. dec. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 9. dec. 21:48 UTC

Tirgus saruna

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

2025. g. 9. dec. 21:36 UTC

Peļņas

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

2025. g. 9. dec. 21:36 UTC

Peļņas

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

2025. g. 9. dec. 21:36 UTC

Peļņas

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

2025. g. 9. dec. 21:36 UTC

Peļņas

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

2025. g. 9. dec. 21:36 UTC

Peļņas

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

2025. g. 9. dec. 20:28 UTC

Tirgus saruna

Oil Futures Decline for Second Straight Session -- Market Talk

2025. g. 9. dec. 20:27 UTC

Iegādes, apvienošanās, pārņemšana

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

2025. g. 9. dec. 20:27 UTC

Iegādes, apvienošanās, pārņemšana

Teck Reports Voting Results From Special Meeting of Hldrs

2025. g. 9. dec. 20:26 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

2025. g. 9. dec. 20:21 UTC

Tirgus saruna

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

2025. g. 9. dec. 19:52 UTC

Peļņas

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

2025. g. 9. dec. 19:17 UTC

Peļņas

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

2025. g. 9. dec. 17:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 9. dec. 17:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 9. dec. 17:11 UTC

Peļņas

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Charles River Laboratories International Inc Prognoze

Cenas mērķis

By TipRanks

3.5% augšup

Prognoze 12 mēnešiem

Vidējais 192.5 USD 3.5%

Augstākais 225 USD

Zemākais 165 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Charles River Laboratories International Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

11 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 11 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Charles River Laboratories International Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

117.16 / 144.77Atbalsts un pretestība

Recent bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

182 / 374 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.